Govt plans to shut down two pharma PSUs

The government has decided to close two pharma public sector undertakings and disinvest the other three, Parliament was informed.

“The Department of Pharmaceuticals has five public sector undertakings (PSUs). Out of the five PSUs, the government has taken a decision to close two pharma PSUs, namely:

Indian Drugs & Pharmaceuticals Ltd (IDPL) and
Rajasthan Drugs & Pharmaceuticals Ltd (RDPL),

said D V Sadananda Gowda, Minister of Chemicals and Fertilisers, in response to a question in the Lok Sabha.

The government has also decided to strategically disinvest the other three:

Hindustan Antibiotics Ltd (HAL),
Bengal Chemicals & Pharmaceuticals Ltd (BCPL), and
Karnataka Antibiotics & Pharmaceutical Ltd (KAPL),

The government has offered voluntary retirement benefits to all employees of IDPL and RDPL, Gowda said.

“However, the Committee of Ministers constituted on September 9, 2019, will take necessary decisions pertaining to closure/strategic sale of the pharma public sector undertakings, including the sale of assets and clearance of outstanding liabilities,” he added.

Related Posts

Parliamentary Panel Recommends Decentralisation Of Approval Of All Medical Devices

New Delhi: The Parliamentary Panel on Health and Family Welfare has recommended various significant regulatory changes in the regulation of medical devices, including decentralisation of approval for all medical devices…

Diabetic drug metformin found to act on brain

NEW DELHI:  Cheap, effective and widely trusted, metformin has long been the first choice for treating type 2 diabetes. Now, scientists say the drug works in a way few had…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Parliamentary Panel Recommends Decentralisation Of Approval Of All Medical Devices

Parliamentary Panel Recommends Decentralisation Of Approval Of All Medical Devices

Diabetic drug metformin found to act on brain

Diabetic drug metformin found to act on brain

Hetero debuts semaglutide generic in emerging markets

Hetero debuts semaglutide generic in emerging markets

LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

Stem cell therapy for autism illegal: NMC advisory

Stem cell therapy for autism illegal: NMC advisory